Novartis has confirmed that it is no longer going ahead with a large-scale clinical trial of its cholesterol-lowering therapy Leqvio in the UK, but said other elements of
On Wednesday of JP Morgan week last month, pharmaphorum editor-in-chief Jonah Comstock sat down at the Zeppelin Hotel with Claudia Ulbrich, CEO of Germany-based Cardior, to learn a little more abou
NewAmsterdam Pharma's bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib.
Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte